Epic Sciences

09.24.2018 / San Diego Back to News Listings

Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient Selection

Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. Researchers from Epic and Memorial Sloan Kettering Cancer Center assessed BIND-014 in a Phase II trial (NCT01812746) designed to evaluate the treatment’s efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).

Read the full story on Clinical OMICs.

clinical omics logo.gif